White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome

被引:17
|
作者
Kim, Haesook T. [1 ]
Frederick, David [2 ]
Armand, Philippe [2 ]
Andler, Emily [2 ]
Kao, Grace [2 ]
Cutler, Corey [2 ]
Koreth, John [2 ]
Alyea, Edwin P., III [2 ]
Antin, Joseph H. [2 ]
Soiffer, Robert J. [2 ]
Ritz, Jerome [2 ]
Ho, Vincent T. [2 ]
机构
[1] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Dept Hematol Oncol, Boston, MA 02215 USA
关键词
VERSUS-HOST-DISEASE; LYMPHOCYTE RECOVERY; MONOCYTE RECOVERY; BONE-MARROW; IMPACT; RISK;
D O I
10.1002/ajh.23695
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine whether outcome after allogeneic hematopoietic cell transplantation (HCT) could be estimated by using peripheral white blood cell count (WBC) as a metric that integrates several aspects of HCT recovery, we conducted a retrospective study of 1,109 adult patients who underwent first allogeneic HCT from 2003 through 2009. WBC at 1-3 months after HCT was categorized as low (<2), normal (2-10), and high (>10 x 10(9) cells/L). Overall survival (OS) and progression-free survival (PFS) were lower for patients with low or high WBC at 1-3 months after HCT (P<0.0001). We developed a predictive three-group risk model based on the pattern of WBC recovery early after HCT. Five-year OS was 47, 30, and 15% (P<0.0001) and 5-year PFS was 39, 22, and 14% for patients in the three different risk groups (P<0.0001). The pattern of WBC recovery early after HCT provides prognostic information for relapse, nonrelapse mortality, progression-free survival, and overall survival. A scoring system based on the trajectory of the WBC in the first 3 months after HCT can effectively stratify patients into three groups with different PFS and OS. If validated, this system could be useful in the clinical management of patients after HCT, and to stratify patients enrolled on HCT clinical trials. Am. J. Hematol. 89:591-597, 2014. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:591 / 597
页数:7
相关论文
共 50 条
  • [31] Clinical effects of tacrolimus blood concentrations early after allogeneic hematopoietic stem cell transplantation
    Kubo, Hiroyuki
    Imataki, Osamu
    Fukumoto, Tetsuya
    Ishida, Tomoya
    Kubo, Yukiko Hamasaki
    Yoshida, Shunsuke
    Uemura, Makiko
    Fujita, Haruyuki
    Kadowaki, Norimitsu
    CYTOTHERAPY, 2024, 26 (05) : 472 - 481
  • [32] Impact of plasmacytoid dendritic cell recovery on outcome after allogeneic stem cell transplantation
    Peric, Z.
    Cahu, X.
    Malard, F.
    Brissot, E.
    Clavert, A.
    Chevallier, P.
    Guillaume, T.
    Delaunay, J.
    Moreau, P.
    Gregoire, M.
    Gaugler, B.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S10 - S10
  • [33] Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation
    Ziliotis, Marie -Julia
    Vauchy, Charline
    Deconinck, Eric
    Berceanu, Ana
    Buchler, Mathias
    Caillard, Sophie
    Couzi, Lionel
    Dussol, Bertrand
    Frimat, Luc
    Hazzan, Marc
    Jaulin, Jean -Paul
    Malvezzi, Paolo
    Latour, Regis Peffault de
    Ducloux, Didier
    Courivaud, Cecile
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (04): : 1127 - 1131
  • [34] Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation
    Savani, Bipin N.
    Mielke, Stephan
    Rezvani, Katayoun
    Montero, Aldemar
    Yong, Agnes S.
    Wish, Laura
    Superata, Jeannine
    Kurlander, Roger
    Singh, Anurag
    Childs, Richard
    Barrett, A. John
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (10) : 1216 - 1223
  • [35] Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation
    Watz, Emma
    Remberger, Mats
    Ringden, Olle
    Ljungman, Per
    Sundin, Mikael
    Mattsson, Jonas
    Uhlin, Michael
    TRANSFUSION, 2015, 55 (10) : 2339 - 2350
  • [36] Comparison of hematopoietic recovery following allogeneic blood stem cell transplantation and allogeneic bone marrow transplantation.
    Bishop, MR
    Tarantolo, SR
    MartinAlgarra, S
    Cowles, K
    Bierman, PJ
    Vose, JM
    Reed, EC
    Gross, TG
    Armitage, JO
    Pavletic, ZS
    Nasrati, K
    Kessinger, A
    BLOOD, 1995, 86 (10) : 1553 - 1553
  • [37] Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population
    Nagatoshi, Y
    Kawano, Y
    Watanabe, T
    Abe, T
    Okamoto, Y
    Kuroda, Y
    Takaue, Y
    Okamura, J
    PEDIATRIC TRANSPLANTATION, 2002, 6 (04) : 319 - 326
  • [38] Kidney Recovery Prognosis after Allogeneic Hematopoietic Stem-Cell Transplantation
    Tsai, Ping-Chi
    Ko, Bor-Sheng
    Huang, Jenq-wen
    Su, Chi-Ting
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [39] Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation
    Radujkovic, Aleksandar
    Kordelas, Lambros
    Bogdanov, Rashit
    Mueller-Tidow, Carsten
    Beelen, Dietrich W.
    Dreger, Peter
    Luft, Thomas
    CANCERS, 2020, 12 (10) : 1 - 20
  • [40] Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation
    Lucarelli, Barbarella
    Merli, Pietro
    Bertaina, Valentina
    Locatelli, Franco
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (03) : 343 - 358